Abstract:Summary Background Health care is experiencing a drive towards digitisation, and many countries are implementing national health data resources. Although a range of cancer risk models exists, the utility on a population level for risk stratification across cancer types has not been fully explored. We aimed to close this gap by evaluating pan-cancer risk models built on electronic health records across the Danish population with validation in the UK Biobank. Methods In this retrospective modelling and validation study, data for model development and internal validation were derived from the following Danish health registries: the Central Person Registry, the Danish National Patient Registry, the death registry, the cancer registry, and full-text medical records from secondary care records in the capital region. The development data included adults aged 16–86 years without previous malignant cancers in the time period from Jan 1, 1995, to Dec 31, 2014. The internal validation period was from Jan 1, 2015, to April 10, 2018, and the data included all adults without a previous indication of cancer aged 16–75 years on Dec 31, 2014. The external validation cohort from the UK Biobank included all adults without a previous indication of cancer aged 50–75 years. We used time-dependent Bayesian Cox hazard models built on the combined medical history of Danish individuals. A set of 1392 covariates from available clinical disease trajectories, text-mined basic health factors, and family histories were used to train predictive models of 20 major cancer types. The models were validated on cancer incidence between 2015 and 2018 across Denmark and on individuals in the UK Biobank. The primary outcomes were discrimination and calibration performance. Findings From the Danish registries, we included 6 732 553 individuals covering 60 million hospital visits, 90 million diagnoses, and a total of 193 million life-years between Jan 1, 1978, and April 10, 2018. Danish registry data covering the period from Jan 1, 2015, to April 10, 2018, were used to internally validate risk models, containing a total of 4 248 491 individuals who remained at risk of a primary malignant cancer diagnosis and 67 401 cancer cases recorded. For the external validation, we evaluated the same time period in the UK Biobank covering 377 004 individuals with 11 486 cancer cases. The predictive performance of the models on Danish data showed good discrimination (concordance index 0·81 [SD 0·08], ranging from 0·66 [95% CI 0·65–0·67] for cervix uteri cancer to 0·91 [0·90–0·92] for liver cancer). Performance was similar on the UK Biobank in a direct transfer when controlling for shifts in the age distribution (concordance index 0·66 [SD 0·08], ranging from 0·55 [95% CI 0·44–0·66] for cervix uteri cancer to 0·78 [0·77–0·79] for lung cancer). Cancer risks were associated, in addition to heritable components, with a broad range of preceding diagnoses and health factors. The best overall performance was seen for cancers of the digestive system (oesophageal, stomach, colorectal, liver, and pancreatic) but also thyroid, kidney, and uterine cancers. Interpretation Data available in national electronic health databases can be used to approximate cancer risk factors and enable risk predictions in most cancer types. Model predictions generalise between the Danish and UK health-care systems. With the emergence of multi-cancer early detection tests, electronic health record-based risk models could supplement screening efforts. Funding Novo Nordisk Foundation and the Danish Innovation Foundation.

A pancreatic cancer risk prediction model (Prism) developed and validated on large-scale US clinical data

Prediction Model for Pancreatic Cancer Risk in the General Japanese Population

Abstract LB550: AI predicts risk of pancreatic cancer from disease trajectories using real-world electronic health records (EHRs) from Denmark and the USA

An Integrative Pancreatic Cancer Risk Prediction Model in the UK Biobank

A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories

Development and validation of a risk prediction model for acute care use among patients with advanced cancer on clinical trials.

Development of a Breast Cancer Risk Prediction Model Integrating Monogenic, Polygenic, and Epidemiologic Risk

Predicting risk of pancreatic cancer in individuals with new-onset type-2 diabetes in primary care: protocol for the development and validation of a clinical prediction model (QPancreasD)

Development and Validation of a Survival Prediction Model for Patients with Pancreatic Cancer

Genetic and Pharmacological Interrogation of Cancer Vulnerability Using a Multiplexed Cell Line Screening Platform

Predicting Pancreatic Cancer in New‐Onset Diabetes Cohort Using a Novel Model With Integrated Clinical and Genetic Indicators: A Large‐Scale Prospective Cohort Study

Clinical Prediction Models for Pancreatic Cancer in General and At-Risk Populations: A Systematic Review

From a genomic risk model to clinical trial implementation in a learning health system: the ProGRESS Study

Early Prediction of Prostate Cancer Risk in Younger Men Using Polygenic Risk Scores and Electronic Health Records

Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction

Machine Learning Models for Pancreatic Cancer Risk Prediction Using Electronic Health Record Data - A Systematic Review and Assessment

Early breast cancer risk detection: a novel framework leveraging polygenic risk scores and machine learning

Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools

Pancreatic Cancer Prediction Through an Artificial Neural Network

Utility of polygenic risk scores in UK cancer screening: a modelling analysis

Multi-cancer risk stratification based on national health data: a retrospective modelling and validation study